E-ISSN 2636-834X
 
2023, Vol: 13, Issue: 1
13/1Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

COPYRIGHT FORM

Review Article 


The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression

Michael Tang, David N. Osser.

Cited By: 2

Abstract
Background: The Psychopharmacology Algorithm Project at the Harvard South Shore Program (PAPHSS) has published evidence-supported algorithms for the pharmacological treatment of major depressive disorder with psychotic features (psychotic depression) in 1998 and 2008. This article is an update for the 2008 algorithm.

Method: Using similar methodology as with the 2008 update, PubMed and EMBASE searches were conducted to identity relevant literature in the English language from November 2007 through July 2012. Articles were evaluated for quality of the data and for whether they provided additional evidence support for previous recommendations or prompted changes to the prior algorithm.

Results: Minor changes were made to the algorithm: most prior recommendations were upheld. The most effective treatment for hospitalized, severe psychotic depression patients remains electroconvulsive therapy (ECT). The combination of an antidepressant (tricyclic [TCA], selective serotonin reuptake inhibitor [SSRI], or serotonin-norepinephrine reuptake inhibitor [SNRI]) plus an antipsychotic continues to be the preferred pharmacological modality when ECT is an unavailable/deferred option. Since the last update, new evidence tends to support using venlafaxine ER, a SNRI, as the first choice antidepressant. Regarding the antipsychotic, both olanzapine and quetiapine have new data demonstrating efficacy. Nevertheless, it is suggested that it may be reasonable to try other atypical antipsychotics with more benign safety profiles (e.g. ziprasidone, aripiprazole) as the first choice antipsychotic. New data also suggest at least four months of maintenance therapy is effective. If the first antidepressant-antipsychotic combination produces an unsatisfactory outcome, and ECT is still not acceptable or appropriate, the second pharmacotherapy trial can be with a change in the antidepressant, as was recommended in the 2008 algorithm. After two trials of combination therapy have failed (and, again, ECT is not an option), the algorithm continues to recommend augmentation with lithium. Limited evidence also suggests consideration of a switch to clozapine monotherapy. Augmentation with methylphenidate is a newly mentioned possible option based on very small evidence. When combination therapy is deferred, evidence suggests monotherapy with a TCA may be more effective than an SNRI or SSRI. However, safety issues and possible increased risk of psychosis exacerbation are unfavorable factors for TCA monotherapy. ECT or addition of an antipsychotic should be reconsidered if antidepressant monotherapy failed.

Conclusion: This heuristic further refines the previous PAPHSS analysis of the available evidence for pharmacological treatment of psychotic depression. The validity of the conclusions is limited by the quality and quantity of the literature available: the number of head-to-head prospective trials in psychotic depression is still relatively small. However, this algorithm m

Key words: affective disorders, psychotic, psychotic depression, delusional depression, pharmacological treatment, psychopharmacology


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Michael Tang
Articles by David N. Osser
on Google
on Google Scholar


REFERENCES
1. Hamoda HM, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on psychotic depression. Harv Rev Psychiatry. 2008; 16:235-47. [DOI via Crossref]    [Pubmed]   
2. Osser DN, Patterson RD. Algorithms for the pharmacotherapy of depression: Part One Directions in Psychiatry 1998; 18:303-18.
3. Johnson J, Jowarth E, Weissman MM. The validity of major depression with psychotic features based on a community study Arch Gen Psychiatry 1991; 48:1075-81.
4. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry. 2002; 159:1855-61. [DOI via Crossref]   
5. Coryell W, Lavori P, Endicott J, Keller M, VanEerdewegh M. Outcome in schizoaffective, psychotic, and nonpsychotic depression. Course during a six- to 24-month follow-up. Arch Gen Psychiatry. 1984; 41:787-91. [DOI via Crossref]    [Pubmed]   
6. Ruggero CJ, Kotov R, Carlson GA, Tanenberg-Karant M, Gonzalez DA, Bromet EJ. Diagnostic consistency of major depression with psychosis across 10 years. J Clin Psychiatry. 2011; 72:1207-13. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
7. Tohen M, Khalsa HM, Salvatore P, Vieta E, Ravichandran C, Baldessarini RJ. Two-year outcomes in first-episode psychotic depression the McLean-Harvard First-Episode Project. J Affect Disord. 2012; 136:1-8. [DOI via Crossref]    [Pubmed]   
8. Ansari A, Osser DN. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression. Harv Rev Psychiatry. 2010; 18:36-55. [DOI via Crossref]    [Pubmed]   
9. Bajor LA, Ticlea AN, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on posttraumatic stress disorder. Harv Rev Psychiatry. 2011; 19:240-58. [DOI via Crossref]    [Pubmed]   
10. Osser DN, Dunlop LR. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on generalized social anxiety disorder. Psychopharm Review. 2010; 45:91-8. [DOI via Crossref]   
11. Osser DN, Jalali-Roudsari M, Manschreck T. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry. 2013; 21:in press.
12. Petrides G, Fink M, Husain MM, Knapp RG, Rush AJ, Mueller M, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT 2001; 17:244-53. [DOI via Crossref]    [Pubmed]   
13. Perry P, Morgan D, Smith R, Tsuang M. Treatment of unipolar depression accompanied by delusions. J Affect Disord. 1982; 4:195-200. [DOI via Crossref]   
14. Olfson M, Marcus S, Sackeim HA, Thompson J, Pincus HA. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry. 1998; 155:22-9.
15. Keller J, Schatzberg AF, Maj M. Current issues in the classification of psychotic major depression. Schizophr Bull. 2007; 33:877-85. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
16. Navarro V, Gasto C, Torres X, Masana G, Penades R, Guarch J, et al. Continuation/maintenance treatment with nortriptyline versus combined nortriptyline and ECT in late-life psychotic depression: a two-year randomized study. Am J Geriatr Psychiatry. 2008; 16:498-505. [DOI via Crossref]    [Pubmed]   
17. Meyers BS, Klimstra SA, Gabriele M, Hamilton M, Kakuma T, Tirumalasetti F, et al. Continuation treatment of delusional depression in older adults. American Journal of Geriatric Psychiatry. 2001; 9:415-22.
18. Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001; 285:1299-307. [DOI via Crossref]    [Pubmed]   
19. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, third edition. American Journal of Psychiatry. 2010; 167:1-118.
20. National Collaborating Centre for Mental Health. The treatment and management of depression in adults: NICE clinical guideline 90. London; Leicester, UK: Gaskell and the British Psychological Society, 2009.
21. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012; 73:486-96. [DOI via Crossref]    [Pubmed]   
22. Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA. Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis. Br J Psychiatry. 2006; 188:410-5. [DOI via Crossref]    [Pubmed]   
23. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, et al. The pharmacological treatment of delusional depression. Am J Psychiatry. 1985; 142:430-6.
24. Anton R, Burch E. Amoxapine vs amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry. 1990; 147:1203-8.
25. Nelson JC, Price L, Jatlow P. Neuroleptic dose and desipramine concentration during combined treatment of unipolar delusional depression. American Journal of Psychiatry. 1986; 143:1151-4.
26. Mulsant BH, Sweet RA, Rosen J, Pollock BG, Zubenko GS, Flynn T, et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry. 2001; 62:597-604. [DOI via Crossref]    [Pubmed]   
27. Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety. 1998; 7 Suppl 1:11-7.
28. Vermeiden M, van den Broek WW, Mulder PG, Birkenhager TK. Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients. J Psychopharmacol. 2010; 24:497-502. [DOI via Crossref]    [Pubmed]   
29. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. Journal of Clinical Psychiatry. 1993; 54:338-42.
30. Wolfersdorf M, Barg T, Konig F, Leibfarth M, Grunewald I. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry. 1995; 28:56-60. [DOI via Crossref]    [Pubmed]   
31. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004; 24:365-73. [DOI via Crossref]    [Pubmed]   
32. Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009; 66:838-47. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
33. Blumberger DM, Mulsant BH, Emeremni C, Houck P, Andreescu C, Mazumdar S, et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. J Psychiatr Res. 2011; 45:896-901. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
34. Wijkstra J, Burger H, van den Broek WW, Birkenhager TK, Janzing JG, Boks MP, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand. 2010; 121:190-200. [DOI via Crossref]    [Pubmed]   
35. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004; 161:414-25. [DOI via Crossref]    [Pubmed]   
36. Chiu CC, Chen KP, Liu HC, Lu ML. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol. 2006; 26:504-7. [DOI via Crossref]    [Pubmed]   
37. Smith E, Rothschild AJ, Heo M, Peasley-Miklus C, Caswell M, Papademetriou E, et al. Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. Int Clin Psychopharmacol. 2008; 23:130-7. [DOI via Crossref]    [Pubmed]   
38. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009; 302:1765-73. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
39. Moeller O, Evers S, Deckert J, Baune BT, Dannlowski U, Nguyen DH, et al. The impact of ziprasidone in combination with sertraline on visually-evoked event-related potentials in depressed patients with psychotic features. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31:1440-3. [DOI via Crossref]    [Pubmed]   
40. Matthews JD, Siefert C, Dording C, Denninger JW, Park L, van Nieuwenhuizen AO, et al. An open study of aripiprazole and escitalopram for psychotic major depressive disorder. J Clin Psychopharmacol. 2009; 29:73-6. [DOI via Crossref]    [Pubmed]   
41. Goto M, Yoshimura R, Kakihara S, Shinkai K, Yamada Y, Kaji K, et al. Risperidone in the treatment of psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30:701-7. [DOI via Crossref]    [Pubmed]   
42. Wijkstra J, Burger H, van den Broek WW, Birkenhager TK, Janzing JG, Boks MP, et al. Long-term response to successful acute pharmacological treatment of psychotic depression. J Affect Disord. 2010; 123:238-42. [DOI via Crossref]    [Pubmed]   
43. Aronson T, Shukla S, Hoff A. Continuation therapy after ECT for delusional depression: a naturalistic study of prophylactic treatments and relapse. Convulsive Therapy. 1987; 3:251-9.
44. Schatzberg AF, Rothschild AF. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? American Journal of Psychiatry. 1992; 149:733-45.
45. Khan A, Cohen S, Stowell M, Capwell R, Avery D, Dunner DL. Treatment options in severe psychotic depression. Convulsive Therapy. 1987; 3:93-9.
46. Price LH, Charney DS, Heninger GR. Variability of response to lithium augmentation in refractory depression. American Journal of Psychiatry. 1986; 143:1387-92.
47. Price L, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. American Journal of Psychiatry. 1983; 140:318-22.
48. Birkenhager TK, van den Broek WW, Wijkstra J, Bruijn JA, van Os E, Boks M, et al. Treatment of unipolar psychotic depression: an open study of lithium addition in refractory psychotic depression. J Clin Psychopharmacol. 2009; 29:513-5. [DOI via Crossref]    [Pubmed]   
49. Ranjan R, Meltzer HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry. 1996; 40:253-8. [DOI via Crossref]   
50. Jeyapaul P, Vieweg R. A case study evaluating the use of clozapine in depression with psychotic features. Ann Gen Psychiatry. 2006; 5:20.
51. Dassa D, Kaladjian A, Azorin JM, Giudicelli S. Clozapine in the treatment of psychotic refractory depression. British Journal of Psychiatry. 1993; 163:822-4. [DOI via Crossref]    [Pubmed]   
52. Huang CC, Shiah IS, Chen HK, Mao WC, Yeh YW. Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression. Clin Neuropharmacol. 2008; 31:245-7. [DOI via Crossref]    [Pubmed]   
53. Wharton R, Perel J, Dayton P, Malitz S. A potential clinical use for methylphenidate with tricyclic antidepressants American Journal of Psychiatry. 1971; 127:1619-25.
54. Khan A, Noonan C, Healey W. Is a single tricyclic antidepressant trial an active treatment for psychotic depression? Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1991; 15:765-70.
55. van den Broek WW, Birkenhager TK, Mulder PG, Bruijn JA, Moleman P. A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology (Berl). 2004; 175:481-6.
56. Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. . The Cochrane Database of Systematic Reviews, 2004: Art. No.:CD004044.pub2. [DOI via Crossref]    [DOI via Crossref]   
57. Bruijn JA, Moleman P, Mulder PG, van den Broek WW, van Hulst AM, van der Mast RC, et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology (Berl). 1996; 127:231-7. [DOI via Crossref]   
58. Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. American Journal of Psychiatry. 1996; 153:414-6.
59. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry. 1996; 153:1631-3.
60. Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry. 2000; 61:26-9. [DOI via Crossref]    [Pubmed]   
61. Kishimoto A, Todani A, Miura J, Kitagaki T, Hashimoto K. The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report. Ann Gen Psychiatry. 2010; 9:23. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
62. Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors. Ann Gen Psychiatry. 2009; 8:26. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
63. Kantrowitz JT, Tampi RR. Risk of psychosis exacerbation by tricyclic antidepressants in unipolar Major Depressive Disorder with psychotic features. J Affect Disord. 2008; 106:279-84. [DOI via Crossref]    [Pubmed]   
64. Osser DN. Why physicians do not follow some algorithms and guidelines. Drug Benefit Trends. 2009; 21:345-54.
65. Andreescu C, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007; 68:194-200. [DOI via Crossref]    [Pubmed]   
66. Mulsant BH, Haskett RF, Prudic J, Thase ME, Malone KM, Mann JJ, et al. Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry. 1997; 154:559-61.

This Article Cited By the following articles

Dose Dependent Course of Hyperprolactinemic and Normoprolactinemic Galactorrhea Induced by Venlafaxine
Clin Psychopharmacol Neurosci 2017; 15(2): 181.

1
 
On the Value of Evidence-Based Psychopharmacology Algorithms
Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2013; 23(1): 1.

2
 
How to Cite this Article
Pubmed Style

Michael Tang, David N. Osser. The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression. PBS. 2012; 2(4): 168-179. doi:10.5455/jmood.20121222120547

Web Style

Michael Tang, David N. Osser. The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression. https://www.pbsciences.org/?mno=25068 [Access: March 28, 2023]. doi:10.5455/jmood.20121222120547

AMA (American Medical Association) Style

Michael Tang, David N. Osser. The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression. PBS. 2012; 2(4): 168-179. doi:10.5455/jmood.20121222120547


Vancouver/ICMJE Style

Michael Tang, David N. Osser. The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression. PBS. (2012), [cited March 28, 2023]; 2(4): 168-179. doi:10.5455/jmood.20121222120547


Harvard Style

Michael Tang, David N. Osser (2012) The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression. PBS, 2 (4), 168-179. doi:10.5455/jmood.20121222120547


Turabian Style

Michael Tang, David N. Osser. 2012. The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression. Psychiatry and Behavioral Sciences, 2 (4), 168-179. doi:10.5455/jmood.20121222120547


Chicago Style

Michael Tang, David N. Osser. "The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression." Psychiatry and Behavioral Sciences 2 (2012), 168-179. doi:10.5455/jmood.20121222120547


MLA (The Modern Language Association) Style

Michael Tang, David N. Osser. "The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression." Psychiatry and Behavioral Sciences 2.4 (2012), 168-179. Print. doi:10.5455/jmood.20121222120547


APA (American Psychological Association) Style

Michael Tang, David N. Osser (2012) The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression. Psychiatry and Behavioral Sciences, 2 (4), 168-179. doi:10.5455/jmood.20121222120547


Author LoginReviewer Login
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.
The articles in Psychiatry and Behavioral Sciences are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Copyright © 2023 Psychiatry and Behavioral Sciences All Rights Reserved. Subject to change without notice from or liability to Psychiatry and Behavioral Sciences.
For best results, please use Internet Explorer or Google Chrome

Contact Information